Management tracks: Bailey leaving GSK; plus HHS drug pricing adviser to depart and more

Jack Bailey will step down as president of U.S. Pharmaceuticals at GlaxoSmithKline plc (LSE:GSK; NYSE:GSK) at year end. He will be replaced by Maya Martinez-Davis, who is regional president for Latin America at the EMD Serono unit of Merck KGaA (Xetra:MRK). Martinez-Davis will start in mid-September and will assume responsibility for the U.S. pharmaceuticals business on Jan. 1, 2020. Bailey will be a strategic consultant to GSK through next year.

John O'Brien is stepping down as senior adviser to HHS Secretary Alex Azar for drug pricing reform. John Brooks, who is principal deputy director of the Center for Medicare, will expand his role to include drug pricing policy. As the Trump administration’s point person on drug pricing strategy, O’Brien was one of the architects of the administration’s drug pricing blueprint and a defender of the international pricing index scheme (see "Newly Named Azar Adviser O'Brien Defends Pricing Index")...